Advertisement

Topics

RIEMSER Arzneimittel AG Company Profile

07:44 EST 10th December 2018 | BioPortfolio

RIEMSER Arzneimittel AG is a medium-sized pharmaceutical company engaging in research and headquartered in the West Pomeranian town of Greifswald - Island of Riems. The stockholding company (AG) operates several branches in Germany and produces advanced substances and medicinal products to be applied in most different areas for both humans and animals. The preparations are sold globally. The company was founded as RIEMSER Tierarzneimittel GmbH in 1990 and privatised in 1992. Since then, turnover has risen from one million euros to 44 million euros in 2005. The number of employees increased from 30 to 380 within the same period.The company is boosting its intensive research work by a budget of five million euros in 2006. The Human segment focuses on biotechnological medicinal products for treating tumourous and immunological diseases. The Veterinary segment develops vaccines and immunoglobulins. Partners of the research and development department are well-known research institutes and universities in Germany and Europe. Institutes of the medical faculties of the universities of Rostock and Greifswald as well as the renowned Friedrich-Löffler-Institut Insel Riems (FLI) are involved in the research work in the federal state of Mecklenburg–West Pomerania.

Location

An der Wiek 7
Greifswald
Insel Riems
17493
Germany

Contact

Phone: 49 38351 76-0
Fax: 49 38351 308
Email: info@RIEMSER.de


News Articles [86 Associated News Articles listed on BioPortfolio]

DGAP-News: STADA Arzneimittel AG: STADA wird Mehrheitsaktionärin der BIOCEUTICALS Arzneimittel AG (deutsch)

STADA Arzneimittel AG: STADA wird Mehrheitsaktionärin der BIOCEUTICALS Arzneimittel AG DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Sonstiges STADA Arzneimittel AG: STADA wird Mehrheitsaktion...

DGAP-News: STADA Arzneimittel AG: Bekanntgabe vom Ergebnis des

STADA Arzneimittel AG: Bekanntgabe vom Ergebnis des Rückkaufangebots betreffend die STADA-Anleihe 2015/2022 DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Anleihe STADA Arzneimittel AG: Bekannt...

DGAP-News: STADA Arzneimittel AG: Beschlussergebnisse der

STADA Arzneimittel AG: Beschlussergebnisse der Gläubigerversammlung zur STADA-Anleihe 2015/2022 DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Anleihe STADA Arzneimittel AG: Beschlussergebnisse...

Stada Arzneimittel: Aus die Maus?

Mit einer ziemlich rabiaten Methode wollen die Mehrheitseigentümer bei Stada Arzneimittel die Kleinanleger loswerden. Wie Nidda Healthcare mitteilte, soll Stada von der Börse genommen werden. Damit....

DGAP-News: STADA Arzneimittel AG: Aufforderung zu Anpassungen der

STADA Arzneimittel AG: Aufforderung zu Anpassungen der STADA-Anleihe 2015/2022 DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Anleihe STADA Arzneimittel AG: Aufforderung zu Anpassungen der STAD...

STADA Arzneimittel AG Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

STADA Arzneimittel AG Strategy, SWOT and Corporate Finance ReportSummarySTADA Arzneimittel AG Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. ...

DGAP-News: STADA Arzneimittel AG: Hauptversammlung stimmt Tagesordnungspunkten mit großer Mehrheit zu (deutsch)

STADA Arzneimittel AG: Hauptversammlung stimmt Tagesordnungspunkten mit großer Mehrheit zu DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Hauptversammlung STADA Arzneimittel AG: Hauptversammlun...

STADA Arzneimittel AG: Strategischer Ausbau des OTC-Portfolios geht weiter

Bad Marienberg (www.anleihencheck.de) - Die STADA Arzneimittel AG (ISIN DE0007251803/ WKN 725180) baut ihre Position im Bereich OTC-Healthcare-Markenprodukte weiter aus, so das Unternehmen in einer...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Frequent Adverse Drug Reactions, and Medication Groups under Suspicion.

The adverse drug reaction database of the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) contains reports of suspected adverse dru...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects

The purpose of this trial is to compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co., Ltd and ISMO Retar...

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

An open label, randomized controlled study in a Norwegian population with meibomian gland dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch & Lom...

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Companies [7 Associated Companies listed on BioPortfolio]

RIEMSER Inc.

RIEMSER Inc., with U.S. headquarters in Research Triangle Park, NC, distributes leading products in the field of bone regeneration and dental implants, including Cerasorb(R), EpiGuide(R), Inion GTR(TM...

RIEMSER Arzneimittel AG

RIEMSER Arzneimittel AG is a medium-sized pharmaceutical company engaging in research and headquartered in the West Pomeranian town of Greifswald - Island of Riems. The stockholding company (AG) opera...

Bundesinstitut für Arzneimittel und Medizinprodukte

Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) ist eine selbständige Bundesoberbehörde im Geschäftsbereich des Bundesministeriums für Gesundheit. Aufgrund des Gesetzes über die ...

Laves-Arzneimittel GmbH

Nil

HERMES PHARMA

HERMES PHARMA specializes in developing and manufacturing user-friendly solid oral dosage forms – including effervescent and chewable tablets, instant drinks and orally disintegrating granules...

More Information about "RIEMSER Arzneimittel AG" on BioPortfolio

We have published hundreds of RIEMSER Arzneimittel AG news stories on BioPortfolio along with dozens of RIEMSER Arzneimittel AG Clinical Trials and PubMed Articles about RIEMSER Arzneimittel AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of RIEMSER Arzneimittel AG Companies in our database. You can also find out about relevant RIEMSER Arzneimittel AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record